MaxCyte Share News (MXCT)

MaxCyte inks platform licensing deal with Lyell

(Sharecast News) - Cell engineering platform technology company MaxCyte announced a strategic platform licence (SPL) agreement with Lyell Immunopharma - a clinical-stage T-cell reprogramming company - on Thursday.

MaxCyte inks strategic platform license with Lyell Immunopharma

(Alliance News) - MaxCyte Inc on Thursday said it has signed a strategic platform license with Lyell Immunopharma Inc, a clinical stage T cell reprogramming company.

MaxCyte revises guidance after weaker first quarter

(Sharecast News) - Cell engineering specialist MaxCyte saw its shares slide on Thursday, after it updated its revenue guidance for the year on the back of its first quarter performance.

MaxCyte revenue declines, operating loss widens as costs increase

(Alliance News) - MaxCyte Inc on Thursday reported a widened operating loss in the first quarter of 2023 as revenue fell and costs were higher.

IN BRIEF: MaxCyte signs strategic platform license with Walking Fish

MaxCyte Inc - cell-engineering technology platform based in US state of Maryland - Signs a strategic platform license with Walking Fish Therapeutics Inc, a biotechnology company that is "rapidly advancing B cell-based therapeutics." Under the terms of the agreement, Walking Fish obtains non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation technology and ExPERT platform. In return, MaxCyte is entitled to receive platform licensing fees, clinical milestone payments and sales-based payments.

UK earnings, trading statements calendar - next 7 days

IN BRIEF: MaxCyte Chair Richard Douglas buys USD350,000 in shares

MaxCyte Inc - cell-engineering technology platform based in US state of Maryland - Non-Executive Chair Richard Douglas buys 80,000 shares at average USD4.32, worth USD345,480, on Wednesday. Now has 100,000 shares, a 0.1% stake.

MaxCyte installs Douglas Swirsky as its new finance chief

(Sharecast News) - Cell engineering technology company MaxCyte announced the appointment of Douglas Swirsky as its new chief financial officer on Tuesday.

MaxCyte appoints new chief financial officer, effective immediately

(Alliance News) - MaxCyte Inc on Tuesday said it appointed Douglas Swirsky as its new chief financial officer, effective immediately.

MaxCyte expecting strong 2023 after decent results

(Sharecast News) - Cell engineering specialist MaxCyte reported total revenue of $12.4m in the fourth quarter of 2022 on Thursday, making for an increase of 22% year-on-year.

MaxCyte revenue up as growth expected in 2023; net loss widens

(Alliance News) - MaxCyte Inc on Thursday said revenue was up by a third in 2022, as it expects further growth in 2023.

IN BRIEF: MaxCyte names members of new scientific advisory board

MaxCyte Inc - Maryland, US-based cell-engineering focused company - Forms new scientific advisory board that will reflect on research in molecular design and cell engineering and gain an understanding of translational development, in order to leverage the benefits of impactful discoveries for therapeutic applications. Board will include scientists, Oliver Rando, Marcela Maus, Avery Posey and Nako Nakatsuka.

UK earnings, trading statements calendar - next 7 days

MaxCyte revenue grows in 2022, expects further revenue climb in 2023

(Alliance News) - MaxCyte Inc on Tuesday announced a higher revenue for 2022, and said it anticipates revenue to grow further during 2023.

MaxCyte flags 2022 revenue growth, sets new guidance

(Sharecast News) - Cell engineering technology company MaxCyte said in an update on Tuesday that it was expecting full-year 2022 total revenue of $44.3m, which would represent growth of 31% over 2021.